A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.
There is a critical need to non-invasively and remotely manipulate cells at a distance, particularly for translational applications in animals and humans, researchers said.
The team developed an innovative approach to use mechanogenetics—a field of science that focuses on how physical forces and changes in the mechanical properties of cells and tissues influence gene expression—for the remote control of gene and cell activations. Researchers used ultrasound to mechanically perturb T cells, and then converted the mechanical signals into genetic control of cells.
In this study, researchers show how their remote-controlled mechanogenetics system can be used to engineer chimeric antigen receptor (CAR)-expressing T cells that can target and kill cancer cells. The engineered CAR-T cells have mechano-sensors and genetic transducing modules that can be remotely activated by ultrasound via microbubble amplification.
“CAR-T cell therapy is becoming a paradigm-shifting therapeutic approach for cancer treatment,” said bioengineering professor Peter Yingxiao Wang at the University of California San Diego. “However, major challenges remain before CAR-based immunotherapy can become widely adopted. For instance, the non-specific targeting of CAR-T cells against nonmalignant tissues can be life-threatening. This work could ultimately lead to an unprecedented precision and efficiency in CAR-T cell immunotherapy against solid tumors, while minimizing off-tumor toxicities.”
The team brings together the laboratories of professors Wang and Shu Chien, both bioengineering professors at the Jacobs School of Engineering and the Institute of Engineering in Medicine at UC San Diego, in collaboration with professors Kirk Shung of the University of Southern California and Michel Sadelain at Memorial Sloan Kettering Cancer Center in New York. Researchers present their findings in the Jan. 15 issue of the Proceedings of the National Academy of Sciences, with UC San Diego Ph.D. candidate Yijia Pan as the first author.
Researchers found that microbubbles conjugated to streptavidin can be coupled to the surface of a cell, where mechanosensitive Piezo1 ion channels are expressed. Upon exposure to ultrasound waves, microbubbles vibrate and mechanically stimulate Piezo1 ion channels to let calcium ions inside the cell. This triggers downstream pathways, including calcineurin activation, NFAT dephoshorylation and translocation into the nucleus. The nucleus-translocated NFAT can bind to upstream response elements of genetic transducing modules to initiate gene expression of chimeric antigen receptor (CAR) for the recognition and killing of target cancer cells.
The Latest on: CAR-T cell therapy
- Medicare Makes Move Toward CAR T-Cell Therapy Coverage on February 19, 2019 at 8:14 am
To date, there is no national Medicare policy in place to provide coverage for chimeric antigen receptor (CAR) T-cell therapies, which have shown to be a successful treatment for certain patients with ... […]
- CMS Proposes Coverage With Evidence Development for CAR T-Cell Therapy for Cancers on February 18, 2019 at 1:24 pm
The Centers for Medicare & Medicaid Services (CMS) has proposed to cover chimeric antigen receptor (CAR) T-cell therapies approved by the FDA, under “Coverage with Evidence Development,” according to ... […]
- CAR T-Cell Therapy vs Standard of Care in Non-Hodgkin Lymphoma on February 18, 2019 at 9:11 am
Today we are discussing CAR T-cell therapy for non-Hodgkin lymphoma with Dr. Edward Copelan, Chair of the department of hematologic oncology and blood disorders at the Levine Cancer Institute in North ... […]
- Medicare could start covering CAR T-Cell therapy under new CMS proposal on February 18, 2019 at 7:28 am
A new proposal from the Centers for Medicare and Medicaid means that Medicare could cover CAR T-cell therapy as a treatment for cancer, dependent on specific patient safety and monitoring ... […]
- Global Gene Therapy Research Report 2019: Technologies, Markets & Companies, 2017-2027 with Analysis of CRISPR-Cas9 and CAR-T Cell Therapies on February 18, 2019 at 3:15 am
DUBLIN, Feb. 18, 2019 /PRNewswire/ -- The "Gene Therapy - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering. Gene therapy can be bro... […]
- CMS looks to expand Medicare coverage to CAR-T therapy on February 15, 2019 at 1:59 pm
The Centers for Medicare & Medicaid Services revealed that it intends to allow Medicare to pay for chimeric antigen receptor (CAR) T-cell therapy, in which oncologists use a patient’s own immune syste... […]
- Medicare proposes coverage for new, expensive cancer treatment on February 15, 2019 at 10:20 am
Medicare currently isn't required to pay for it. Under the proposal, individuals who use Medicare to pay for CAR T-cell therapy would have to be monitored for two years post-treatment to inform ... […]
- CAR T-Cell Therapy in Non-Hodgkin Lymphoma Patients on February 15, 2019 at 8:42 am
Edward A. Copelan, MD, Chair of the Department of Hematologic Oncology and Blood Disorders at the Levine Cancer Institute in Charlotte, North Carolina, discusses the use of chimeric antigen receptor ( ... […]
- Medicare would cover CAR-T cell therapies under new CMS proposal on February 15, 2019 at 8:15 am
CAR T-cell therapy is a new form of cancer therapy that harnesses a patient's own immune system to fight the disease. There are currently only two approved CAR-T cell therapies, Novartis's NVS, +0.51% ... […]
- Global CAR-T Cell Therapy Market Report 2019: Emerging Treatment Represents One of the Biggest Breakthroughs Since the Introduction of Chemotherapy on February 14, 2019 at 8:23 am
The "Global CAR-T Cell Therapy Market - Market Size, Forecasts, Trials & Trends" report has been added to ResearchAndMarkets.com's offering. CAR-T cell therapy is a remarkably promising treatment ... […]
via Google News and Bing News